Company registration number 03574227 (England and Wales)
GEN-PHARMA (UK) LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
GEN-PHARMA (UK) LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
GEN-PHARMA (UK) LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
31 December 2024
31 March 2024
Notes
£
£
£
£
Current assets
Debtors
3
1
1
Net current assets
1
1
Capital and reserves
Called up share capital
4
1
1

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial period ended 31 December 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The member has not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 9 May 2025 and are signed on its behalf by:
S Johns
Director
Company Registration No. 03574227
GEN-PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information

Gen-Pharma (UK) Limited is a private company limited by shares incorporated in England and Wales. The registered office is 3 Forbury Place, 23 Forbury Road, Reading, United Kingdom, RG1 3JH.

1.1
Reporting period

These accounts cover a shortened period of 9 months to align the Company’s financial period-end with that of other group companies on 31 December 2024. Consequently, the comparative figures are not directly comparable.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Profit and loss account

The company has not traded during the period or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.5
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

GEN-PHARMA (UK) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 3 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

Period
Year
ended
ended
31 December
31 March
2024
2024
Number
Number
Total
3
5
3
Debtors
31 December
31 March
2024
2024
Amounts falling due within one year:
£
£
Other debtors
1
1
4
Called up share capital
31 December
31 March
31 December
31 March
2024
2024
2024
2024
Ordinary share capital
Number
Number
£
£
Issued and not fully paid
Called up share capital not paid of £1 each
1
1
1
1

 

5
Parent company

At the balance sheet date, the Company is a 100% subsidiary undertaking of Ceuta Holdings Limited. Ceuta Holdings Limited was acquired by IQVIA Ltd on 2 May 2024. At that date IQVIA Holdings Inc. became the ultimate controlling party.

 

IQVIA Holdings Inc. is the ultimate controlling party as at the date of approval of these financial statements. This company is incorporated in Delaware, United States of America.

At the balance sheet date, the largest and smallest group in which the results of the Company are consolidated is that headed by IQVIA Holdings Inc., registered at 251 Little Falls Drive, Wilmington, Delaware, 19808 United States. IQVIA Holdings Inc. financial statements are publicly available and may be obtained the company’s website www.iqvia.com.

2024-12-312024-04-01falsefalsetrue12 May 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityD CumiskeyS JohnsP PitaleC SkinnerA TemplemanJTC (UK)  Limited035742272024-04-012024-12-31035742272024-12-31035742272024-03-3103574227core:ShareCapital2024-12-3103574227core:ShareCapital2024-03-3103574227core:ShareCapitalOrdinaryShareClass12024-12-3103574227core:ShareCapitalOrdinaryShareClass12024-03-3103574227bus:Director22024-04-012024-12-31035742272023-04-012024-03-3103574227core:WithinOneYear2024-12-3103574227core:WithinOneYear2024-03-3103574227bus:OrdinaryShareClass12024-04-012024-12-3103574227bus:OrdinaryShareClass12024-12-3103574227bus:OrdinaryShareClass12024-03-3103574227bus:EntityNoLongerTradingButTradedInPast2024-04-012024-12-3103574227bus:PrivateLimitedCompanyLtd2024-04-012024-12-3103574227bus:SmallCompaniesRegimeForAccounts2024-04-012024-12-3103574227bus:FRS1022024-04-012024-12-3103574227bus:AuditExemptWithAccountantsReport2024-04-012024-12-3103574227bus:Director12024-04-012024-12-3103574227bus:Director32024-04-012024-12-3103574227bus:Director42024-04-012024-12-3103574227bus:Director52024-04-012024-12-3103574227bus:CompanySecretary12024-04-012024-12-3103574227bus:FullAccounts2024-04-012024-12-31xbrli:purexbrli:sharesiso4217:GBP